Anwesha Dey

9PUBLICATIONS
108CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 08, 2026
Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells.

|Mar 05, 2026
The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.

Juliette Roels, Hamid Ghaedi, Jayaram Kancherla

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Jul 08, 2025
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).

Kyung W Song, Christy C Ong, Eva Lin

|Feb 18, 2025
Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition.

Sayantanee Paul, Thijs J Hagenbeek, Julien Tremblay

|Jun 05, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.

Thijs J Hagenbeek, Jason R Zbieg, Marc Hafner

Pageof 2

Frequent Collaborators

3 joint publications

Danilo Maddalo

3 joint publications

Xiaosai Yao

3 joint publications

Nicole M Sodir

3 joint publications

Marc Hafner